Business Context and Reporting Period
Company: Immuron Ltd (ASX: IMC, NASDAQ: IMRN)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended June 30, 2017
Business Overview: Immuron is a clinical-stage biopharmaceutical company developing oral polyclonal antibodies for gastrointestinal diseases. Its lead candidates are IMM-124E (for Non-Alcoholic Steatohepatitis/NASH) and IMM-529 (for Clostridium difficile). The company also markets Travelan, an over-the-counter (OTC) preventative for Traveler's Diarrhea, and recently launched Protectyn for gut dysbiosis.
Key Financial Metrics (AUD$)
| Metric | 2017 | 2016 | 2015 |
|---|---|---|---|
| Operating Revenue | 1,396,197 | 1,001,077 | 1,002,380 |
| Total Revenue & Other Income | 3,010,570 | 2,540,092 | 2,593,401 |
| Gross Profit | 1,058,651 | 699,642 | 686,252 |
| Net Loss | (6,804,154) | (7,068,767) | (2,691,820) |
| Cash & Cash Equivalents | 3,994,924 | 2,290,639 | 3,116,074 |
| Total Assets | 8,286,491 | 8,827,484 | 6,018,412 |
| Total Liabilities | 1,711,565 | 3,886,921 | 1,207,810 |
| Accumulated Deficit | (49,528,486) | (42,821,357) | (36,072,810) |
Note: Financial statements are prepared in Australian Dollars (AUD) under IFRS. "Other Income" is heavily influenced by Australian R&D Tax Concession refunds (A$1.58M in 2017).
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 39.5% to A$1.40M, driven by the expansion of Travelan sales into the U.S. and China markets.
- Expense Increases: Research and Development (R&D) expenses rose 27.8% to A$4.63M due to the acceleration of the Phase II NASH clinical trial (IMM-124E). Marketing and Promotion expenses increased 62% to A$790K to support new market launches.
- Inventory Impairment: A significant one-time charge of A$136,494 was recorded for expired colostrum inventory, compared to A$4,176 in 2016.
- Financing Activity: The company completed a U.S. IPO in June 2017, raising net proceeds of approximately US$5.67M. This significantly improved liquidity, increasing cash balances by 74% year-over-year.
- Debt Reduction: Total liabilities decreased by 56% to A$1.71M, primarily due to the repayment of convertible notes and related borrowings.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Clinical Milestones: Top-line results for the Phase II NASH trial (IMM-124E) are expected in Q1 2018. The Phase II Alcoholic Steatohepatitis (ASH) trial results are expected in Q1 2019, and Pediatric NASH results in Q4 2018.
- CDI Program: IMM-529 (C. difficile) has completed pre-clinical studies; a Phase I/II trial in Israel commenced in late 2017.
- Liquidity: Management believes current cash reserves, combined with anticipated R&D tax refunds and Travelan sales growth, are sufficient to fund operations for at least 12 months. However, additional financing will be required for long-term objectives.
Risks and Contingencies
- Internal Controls: Management identified material weaknesses in internal control over financial reporting as of June 30, 2017, related to monitoring controls and review processes. This resulted in the restatement of prior period financials.
- Profitability: The company has incurred losses since inception and expects to continue incurring losses for the foreseeable future. It has never generated revenue from prescription products.
- Regulatory & Clinical Risk: Success depends on clinical trial outcomes and regulatory approvals (FDA, TGA, EMA). Failure in trials or delays could materially harm the business.
- Manufacturing: The company relies on a single manufacturer (Synlait Milk) for its lead compound and contract manufacturers for finished products.
Investor Verification Checklist
- Cash Runway: Verify if the A$4.0M cash balance is sufficient to fund the NASH Phase II trial through the expected Q1 2018 readout without immediate dilution.
- Internal Controls: Review the specific remediation plan for the identified material weaknesses in financial reporting to ensure future data reliability.
- R&D Tax Refund Timing: Confirm the actual receipt date of the A$1.5M R&D tax concession refund, which is currently recorded as a receivable.
- Clinical Data: Monitor the upcoming Q1 2018 interim analysis for IMM-124E to validate the efficacy signals (ALT/AST reduction) reported in July 2017.
- Share Dilution: Assess the impact of outstanding warrants (701,500 ADSs) and options (approx. 63.7M ordinary shares) on future share count.